Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
Joost Boeckmans, Alessandra Natale, Matthias Rombaut, et al.
Cells (2019) Vol. 9, Iss. 1, pp. 37-37
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities
Yankai Wen, Joeri Lambrecht, Cynthia Ju, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 45-56
Open Access | Times Cited: 465
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 235
Fructose and the Liver
Pablo Muriel, Pedro López‐Sánchez, Erika Ramos‐Tovar
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 13, pp. 6969-6969
Open Access | Times Cited: 107
Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
Raghu Ramanathan, Ahmad H. Ali, Jamal A. Ibdah
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7280-7280
Open Access | Times Cited: 98
Treating NASH by targeting peroxisome proliferator-activated receptors
Bart Staels, Laura Butruille, Sven Francque
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1302-1316
Open Access | Times Cited: 44
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
Allison Soto, Colby Spongberg, Alessandro Martinino, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 397-397
Open Access | Times Cited: 20
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
Piero Portincasa, Mohamad Khalil, Laura Mahdi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5640-5640
Open Access | Times Cited: 16
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Anne Fougerat, Alexandra Montagner, Nicolas Loiseau, et al.
Cells (2020) Vol. 9, Iss. 7, pp. 1638-1638
Open Access | Times Cited: 112
In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Pierre‐Antoine Soret, Julie Magusto, Chantal Housset, et al.
Journal of Clinical Medicine (2020) Vol. 10, Iss. 1, pp. 36-36
Open Access | Times Cited: 95
PPAR-Mediated Toxicology and Applied Pharmacology
Yue Xi, Yunhui Zhang, Sirui Zhu, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 352-352
Open Access | Times Cited: 82
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications
Maria Jiménez Ramos, Lucia Bandiera, Filippo Menolascina, et al.
iScience (2021) Vol. 25, Iss. 1, pp. 103549-103549
Open Access | Times Cited: 73
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4305-4305
Open Access | Times Cited: 54
Dynamic human liver proteome atlas reveals functional insights into disease pathways
Lili Niu, Philipp E. Geyer, Rajat Gupta, et al.
Molecular Systems Biology (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 46
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
Mathias B. Møllerhøj, Sanne Skovgård Veidal, Kirstine Tølbøl Thrane, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 5, pp. 1167-1186
Open Access | Times Cited: 45
New Drugs for Hepatic Fibrosis
Liang Shan, Fengling Wang, Dandan Zhai, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 44
Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model
Ying Shi, Xiaoguang Yang, Shuyue Wang, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
FXR: structures, biology, and drug development for NASH and fibrosis diseases
Siyu Tian, Shuming Chen, Chengxi Pan, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1120-1132
Open Access | Times Cited: 38
Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
Stephen Malnick, Pavel Alin, Marina Somin, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 16226-16226
Open Access | Times Cited: 37
Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
Zeyu Wang, Du Huiqing, Ying Zhao, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 25
Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Neha Bhat, Arya Mani
Nutrients (2023) Vol. 15, Iss. 10, pp. 2323-2323
Open Access | Times Cited: 24
NAFLD Preclinical Models: More than a Handful, Less of a Concern?
Yvonne Oligschlaeger, Ronit Shiri‐Sverdlov
Biomedicines (2020) Vol. 8, Iss. 2, pp. 28-28
Open Access | Times Cited: 55
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 13, pp. 1637-1649
Closed Access | Times Cited: 53
Upregulation of miR-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: Emphasis on caspase-2 signaling inhibition
Marwa O. El-Derany, Sherihan G. AbdelHamid
Biochemical Pharmacology (2021) Vol. 190, pp. 114624-114624
Closed Access | Times Cited: 44
Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance
Siyer Roohani, Frank Tacke
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7249-7249
Open Access | Times Cited: 44
Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview
Carlos Villarroel-Vicente, Sergio Gutiérrez-Palomo, Jordi Ferri, et al.
European Journal of Medicinal Chemistry (2021) Vol. 221, pp. 113535-113535
Closed Access | Times Cited: 42
Page 1 - Next Page

Scroll to top